Meropenem Aurobindo (Meropenem)

Meropenem inhibits bacterial cell wall synthesis by binding to penicillin‑binding proteins, which are essential for the cross‑linking of peptidoglycan strands. This inhibition compromises the structural integrity of the bacterial cell wall, causing osmotic lysis and rapid bactericidal activity against a wide range of Gram‑positive, Gram‑negative and anaerobic organisms.

The dosing regimen for Meropenem Aurobindo is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and local antimicrobial guidelines. Healthcare professionals calculate the appropriate infusion rate and duration for each individual case.

Safety data for meropenem in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians must evaluate the risk‑benefit profile and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Meropenem Aurobindo. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.

Meropenem shares the carbapenem class’s broad‑spectrum activity and resistance to many β‑lactamases, but it has a slightly lower affinity for certain Pseudomonas strains compared with imipenem. It is often preferred for its favorable safety profile, especially regarding lower risk of nephrotoxicity, and its ability to achieve high concentrations in the cerebrospinal fluid for meningitis treatment.

Meropenem Aurobindo should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Once reconstituted, the solution should be used within the time frame recommended by the manufacturer and kept under the same temperature conditions until administration.

Meropenem Aurobindo is administered intravenously, typically as a slow infusion over 15‑30 minutes. The exact infusion rate, dosage, and duration are determined by the treating physician based on infection severity, patient renal function, and institutional protocols.

The most serious adverse events include seizures, especially in patients with renal impairment or high doses, severe allergic reactions such as anaphylaxis, and Clostridioides difficile‑associated colitis. Clinicians should monitor neurological status, renal function, and signs of hypersensitivity throughout treatment.

Meropenem Aurobindo is contraindicated in patients with a known hypersensitivity to meropenem, other carbapenems, or any component of the formulation. Caution is also advised for individuals with a history of seizures, severe renal impairment, or those receiving interacting medications that could increase toxicity.